Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the upcoming Emerging Growth Virtual Conference. The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will present on February 19, 2025, from 3:10 to 3:20 p.m. ET.
Interested parties can access the presentation through the 'Events and Presentations' section of Longeveron's website. The webcast replay will remain available for 180 days after the conference. Questions can be submitted in advance to Questions@EmergingGrowth.com or asked during the live event.
Longeveron (NASDAQ: LGVN), una società biotecnologica nel campo della medicina rigenerativa in fase clinica, ha annunciato la sua partecipazione al prossimo Emerging Growth Virtual Conference. L'azienda, che si concentra sullo sviluppo di terapie cellulari per condizioni legate all'invecchiamento e malattie croniche minacciose per la vita, presenterà il 19 febbraio 2025, dalle 15:10 alle 15:20 ora ET.
Le parti interessate possono accedere alla presentazione attraverso la sezione 'Eventi e Presentazioni' del sito web di Longeveron. La registrazione del webcast sarà disponibile per 180 giorni dopo la conferenza. Le domande possono essere inviate in anticipo a Questions@EmergingGrowth.com o poste durante l'evento dal vivo.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica en etapa clínica especializada en medicina regenerativa, ha anunciado su participación en la próxima Emerging Growth Virtual Conference. La compañía, que se centra en el desarrollo de terapias celulares para condiciones relacionadas con el envejecimiento y enfermedades crónicas que amenazan la vida, presentará el 19 de febrero de 2025, de 3:10 a 3:20 p.m. ET.
Las partes interesadas pueden acceder a la presentación a través de la sección 'Eventos y Presentaciones' en el sitio web de Longeveron. La repetición del webcast estará disponible durante 180 días después de la conferencia. Las preguntas se pueden enviar por adelantado a Questions@EmergingGrowth.com o plantearse durante el evento en vivo.
론제버론 (NASDAQ: LGVN), 임상 단계의 재생 의학 생명공학 회사가 다가오는 Emerging Growth Virtual Conference에 참여한다고 발표했습니다. 생명을 위협하는 만성 노화 관련 질환을 위한 세포 치료 개발에 중점을 둔 이 회사는 2025년 2월 19일 오후 3시 10분부터 3시 20분(동부 표준시)까지 발표할 예정입니다.
관심 있는 분들은 론제버론 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표를 접속할 수 있습니다. 웹캐스트 재방송은 회의 후 180일 동안 제공됩니다. 질문은 사전에 Questions@EmergingGrowth.com으로 보내거나 라이브 이벤트 중에 질문할 수 있습니다.
Longeveron (NASDAQ: LGVN), une entreprise de biotechnologie en phase clinique spécialisée dans la médecine régénérative, a annoncé sa participation à la prochaine Emerging Growth Virtual Conference. L'entreprise, qui se concentre sur le développement de thérapies cellulaires pour des conditions liées à l'âge et des maladies chroniques menaçant la vie, présentera le 19 février 2025, de 15h10 à 15h20 (heure de l'Est).
Les parties intéressées peuvent accéder à la présentation via la section 'Événements et Présentations' du site Web de Longeveron. La rediffusion du webcast sera disponible pendant 180 jours après la conférence. Les questions peuvent être soumises à l'avance à Questions@EmergingGrowth.com ou posées lors de l'événement en direct.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen im Bereich der regenerativen Medizin in der klinischen Phase, hat seine Teilnahme an der bevorstehenden Emerging Growth Virtual Conference angekündigt. Das Unternehmen, das sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische altersbedingte Erkrankungen konzentriert, wird am 19. Februar 2025 von 15:10 bis 15:20 Uhr ET präsentieren.
Interessierte können die Präsentation über den Bereich 'Veranstaltungen und Präsentationen' auf der Website von Longeveron abrufen. Die Aufzeichnung des Webcasts wird 180 Tage nach der Konferenz verfügbar sein. Fragen können im Voraus an Questions@EmergingGrowth.com gesendet oder während der Live-Veranstaltung gestellt werden.
- None.
- None.
MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Details for the Company’s presentation:
| Date: | February 19, 2025 |
| Time: | 3:10 – 3:20 p.m. ET |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the Emerging Growth Virtual Conference?
How long will the LGVN conference presentation replay be available?
How can investors submit questions for Longeveron's (LGVN) presentation?
Where can investors access Longeveron's (LGVN) Emerging Growth Conference presentation?
